Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash from operating activities | 619.69%3.35M | 1.67M | 3.26M | 48.67%22.32M | -114.40%-645K | 84.63%9.33M | 80.50%5.82M | 38.83%15.01M | -47.19%2.25M | 31.97%4.48M |
| Net profit before non-cash adjustment | 386.35%2.27M | --1.99M | --2.8M | 46.59%21.24M | -126.13%-791K | 187.94%10.69M | 13.39%3.79M | 17.09%14.49M | 60.69%4.4M | 10.72%3.03M |
| Total adjustment of non-cash items | 346.70%486K | --704K | --369K | 1,100.04%481.98K | -252.71%-197K | 3,233.33%94K | -23.88%102K | -106.73%-48.2K | -128.78%-308.2K | -69.43%129K |
| -Depreciation and amortization | 349.33%743K | --691K | --603K | 79.82%2.01M | -206.05%-298K | 207.17%857K | -8.13%260K | -9.70%1.12M | -33.34%273.96K | 4.07%281K |
| -Reversal of impairment losses recognized in profit and loss | ---- | --0 | --0 | 82,566.15%53.73K | ---- | ---- | ---- | --65 | ---- | ---- |
| -Disposal profit | -199.21%-125K | ---162K | ---219K | -10.53%-976.42K | 440.54%126K | -118.05%-580K | 21.88%-50K | -109.60%-883.4K | -160.36%-516.4K | 19.57%-37K |
| -Net exchange gains and losses | -153.70%-29K | --297K | --108K | 575.35%231.03K | --54K | -580.00%-48K | 98.78%-1K | 57.28%-48.6K | 111.15%23.4K | --0 |
| -Other non-cash items | -30.38%-103K | ---122K | ---123K | -258.01%-834.93K | 31.30%-79K | -419.23%-135K | -3,466.67%-107K | -1,732.26%-233.22K | ---89.22K | ---115K |
| Changes in working capital | 75.22%601K | ---1.02M | --94K | 4.73%601.69K | -74.07%343K | -208.26%-1.46M | 858.27%1.93M | 125.26%574.54K | -500.08%-1.84M | 455.88%1.32M |
| -Change in receivables | 158.66%630K | --802K | ---1.52M | -953.03%-1.73M | -129.76%-1.07M | 100.08%2K | -15.61%265K | 108.26%202.35K | -202.09%-1.09M | 1,669.12%3.61M |
| -Change in payables | 76.57%-101K | --239K | ---585K | 298.47%1.48M | 65.27%-431K | -291.75%-1.56M | 613.58%1.36M | 111.12%372.18K | 122.45%1.07M | -29.14%-1.24M |
| -Changes in other current assets | ---- | ---- | ---- | --844.79K | 276.84%1.85M | -96.83%100K | 199.01%300K | --0 | ---1.81M | -205.03%-1.05M |
| -Changes in other current liabilities | --72K | ---2.06M | --2.2M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Dividends paid (cash flow from operating activities) | ||||||||||
| Dividends received (cash flow from operating activities) | ||||||||||
| Interest paid (cash flow from operating activities) | ||||||||||
| Interest received (cash flow from operating activities) | 178K | 195K | 199K | 307.56%987.84K | 15,250.09%242.38K | |||||
| Tax refund paid | -349.29%-1.4M | -640K | -796K | -60.57%-4.88M | 216.18%560K | -183.33%-2.16M | -4.01%-882K | 12.07%-3.04M | 6.44%-949.46K | 42.48%-482K |
| Other operating cash inflow (outflow) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating cash flow | 2,610.59%2.13M | --1.23M | --2.67M | 50.84%18.42M | -102.13%-85K | 67.11%7.17M | 107.78%4.94M | 66.02%12.21M | -52.47%1.55M | 56.38%4M |
| Investing cash flow | ||||||||||
| Net PPE purchase and sale | 87.57%-376K | --244K | ---267K | -1,531.66%-8.06M | -901.66%-3.03M | 541.04%763K | -13,866.67%-1.26M | 56.56%-493.94K | 98.02%-9.94K | -542.55%-302K |
| Net investment product transactions | ---- | ---- | ---- | 34.04%-3.26M | --5M | ---- | ---- | -170.43%-4.94M | 6,673.49%58.25K | --0 |
| Dividends received (cash flow from investment activities) | 115.87%20K | --85K | --22K | 101.40%1.15M | -440.54%-126K | 118.05%580K | -21.88%50K | -24.97%571.64K | 141.00%204.64K | -19.57%37K |
| Interest received (cash flow from investment activities) | ---- | ---- | ---- | ---- | -31.30%79K | 419.23%135K | 3,466.67%107K | ---- | ---- | --115K |
| Net changes in other investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -93.74%58.25K | ---- | ---- |
| Investing cash flow | -118.46%-356K | --329K | ---245K | -109.04%-10.17M | 1,385.33%1.93M | 27.84%-3.52M | -1,996.55%-1.1M | -164.23%-4.86M | 259.67%108.95K | -14,900.00%-150K |
| Financing cash flow | ||||||||||
| Net common stock issuance | ---- | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | --0 |
| Increase or decrease of lease financing | ---399K | ---363K | ---364K | -389.79%-867.76K | ---- | ---- | ---- | -154.68%-177.17K | ---- | ---- |
| Cash dividends paid | --0 | ---3.46M | ---4.33M | -25.00%-8.66M | ---1.73M | ---- | ---- | 0.60%-6.93M | -33.83%-633 | --0 |
| Financing cash flow | 76.98%-399K | ---3.83M | ---4.7M | -34.10%-9.53M | ---1.73M | 0.00%-6.93M | --0 | 5.09%-7.11M | 65.61%-177.8K | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | 7.97%29.67M | --31.81M | --33.97M | 2.02%27.48M | 25.86%27.48M | 6.65%31.32M | 2.02%27.48M | 30.17%26.94M | 0.92%25.69M | -4.65%21.84M |
| Current changes in cash | 1,153.64%1.38M | ---2.27M | ---2.27M | -618.97%-1.27M | -97.14%110K | 56.41%-3.28M | 57.66%3.84M | -96.71%245.02K | -44.63%1.48M | 50.57%3.85M |
| Effect of exchange rate changes | -94.44%1K | ---8K | ---5K | -585.04%-226.78K | 500.00%18K | -7.14%-15K | 57.14%-3K | -47.04%46.76K | -36.06%64.76K | 160.00%3K |
| Cash adjustments other than cash changes | --105K | --136K | --127K | 118.37%553.6K | ---- | ---- | ---- | 119.69%253.51K | ---- | ---- |
| End cash Position | 10.66%31.16M | --29.67M | --31.81M | -3.44%26.54M | 9.62%28.16M | 25.86%27.48M | 6.65%31.32M | 2.02%27.48M | 2.02%27.48M | 0.92%25.69M |
| Free cash flow | 156.53%1.76M | --1.09M | --2.33M | -12.33%10.28M | -184.17%-3.11M | 92.65%7.94M | 55.49%3.68M | 88.91%11.72M | -44.19%1.54M | 47.27%3.7M |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.